Title:
Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy

dc.contributor.authorAkash Verma
dc.contributor.authorDigambar Kumar Waiker
dc.contributor.authorNeha Singh
dc.contributor.authorAnima Roy
dc.contributor.authorNamrata Singh
dc.contributor.authorPoorvi Saraf
dc.contributor.authorBhagwati Bhardwaj
dc.contributor.authorSairam Krishnamurthy
dc.contributor.authorSurendra Kumar Trigun
dc.contributor.authorSushant Kumar Shrivastava
dc.date.accessioned2026-02-09T04:33:55Z
dc.date.issued2024
dc.description.abstractAn efficient and promising method of treating complex neurodegenerative diseases like Alzheimer’s disease (AD) is the multitarget-directed approach. Here in this work, a series of quinazoline derivatives (AV-1 to AV-21) were rationally designed, synthesized, and biologically evaluated as multitargeted directed ligands against human cholinesterase (hChE) and human β-secretase (hBACE-1) that exhibit moderate to good inhibitory effects. Compounds AV-1, AV-2, and AV-3 from the series demonstrated balanced and significant inhibition against these targets. These compounds also displayed excellent blood−brain barrier permeability via the PAMPA-BBB assay. Compound AV-2 significantly displaced propidium iodide (PI) from the acetylcholinesterase-peripheral anionic site (AChE-PAS) and was found to be non-neurotoxic at the maximum tested concentration (80 μM) against differentiated SH-SY5Y cell lines. Compound AV-2 also prevented AChE- and self-induced Aβ aggregation in the thioflavin T assay. Additionally, compound AV-2 significantly ameliorated scopolamine and Aβ-induced cognitive impairments in the in vivo behavioral Y-maze and Morris water maze studies, respectively. The ex vivo and biochemical analysis further revealed good hippocampal AChE inhibition and the antioxidant potential of the compound AV-2. Western blot and immunohistochemical (IHC) analysis of hippocampal brain revealed reduced Aβ, BACE-1, APP/Aβ, and Tau molecular protein expressions levels. The pharmacokinetic analysis of compound AV-2 demonstrated significant oral absorption with good bioavailability. The in silico molecular modeling studies of lead compound AV-2 moreover demonstrated a reasonable binding profile with AChE and BACE-1 enzymes and stable ligand−protein complexes throughout the 100 ns run. Compound AV-2 can be regarded as the lead candidate and could be explored more for AD therapy. © 2024 American Chemical Society.
dc.identifier.doi10.1021/acschemneuro.3c00653
dc.identifier.issn19487193
dc.identifier.urihttps://doi.org/10.1021/acschemneuro.3c00653
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/48517
dc.publisherAmerican Chemical Society
dc.subjectacetylcholinesterase
dc.subjectAlzheimer’s disease
dc.subjectamyloid-β
dc.subjectmultitargeting agents
dc.subjectβ-secretase
dc.titleDesign, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy
dc.typePublication
dspace.entity.typeArticle

Files

Collections